Stasi Alessandra, Franzin Rossana, Caggiano Gianvito, Losapio Rosa, Fiorentino Marco, Alfieri Carlo, Gesualdo Loreto, Stallone Giovanni, Castellano Giuseppe
Renal, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari, Bari, Italy.
Nephrology, Dialysis and Renal Transplant Unit, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Blood Purif. 2023;52 Suppl 1(Suppl 1):71-84. doi: 10.1159/000528685. Epub 2023 Jan 24.
Acute kidney injury (AKI) is a common consequence of sepsis with a mortality rate of up to 40%. The pathogenesis of septic AKI is complex and involves several mechanisms leading to exacerbated inflammatory response associated with renal injury. A large body of evidence suggests that inflammation is tightly linked to AKI through bidirectional interaction between renal and immune cells. Preclinical data from our and other laboratories have identified in complement system activation a crucial mediator of AKI. Partial recovery following AKI could lead to long-term consequences that predispose to chronic dysfunction and may also accelerate the progression of preexisting chronic kidney disease. Recent findings have revealed striking morphological and functional changes in renal parenchymal cells induced by mitochondrial dysfunction, cell cycle arrest via the activation of signaling pathways involved in aging process, microvascular rarefaction, and early fibrosis. Although major advances have been made in our understanding of the pathophysiology of AKI, there are no available preventive and therapeutic strategies in this field. The identification of ideal clinical biomarkers for AKI enables prompt and effective therapeutic strategy that could prevent the progression of renal injury and promote repair process. Therefore, the use of novel biomarkers associated with clinical and functional criteria could provide early interventions and better outcome. Several new drugs for AKI are currently being investigated; however, the complexity of this disease might explain the failure of pharmacological intervention targeting just one of the many systems involved. The hypothesis that blood purification could improve the outcome of septic AKI has attracted much attention. New relevant findings on the role of polymethylmethacrylate-based continuous veno-venous hemofiltration in septic AKI have been reported. Herein, we provide a comprehensive literature review on advances in the pathophysiology of septic AKI and potential therapeutic approaches in this field.
急性肾损伤(AKI)是脓毒症的常见后果,死亡率高达40%。脓毒症相关性急性肾损伤的发病机制复杂,涉及多种导致与肾损伤相关的炎症反应加剧的机制。大量证据表明,炎症通过肾细胞与免疫细胞之间的双向相互作用与急性肾损伤紧密相关。我们实验室和其他实验室的临床前数据已确定补体系统激活是急性肾损伤的关键介质。急性肾损伤后的部分恢复可能导致长期后果,使患者易患慢性肾功能障碍,还可能加速已存在的慢性肾脏病的进展。最近的研究结果显示,线粒体功能障碍、通过激活与衰老过程相关的信号通路导致细胞周期停滞、微血管稀疏和早期纤维化可引起肾实质细胞显著的形态和功能变化。尽管我们对急性肾损伤病理生理学的理解取得了重大进展,但该领域尚无可用的预防和治疗策略。识别理想的急性肾损伤临床生物标志物有助于制定及时有效的治疗策略,从而预防肾损伤进展并促进修复过程。因此,使用与临床和功能标准相关的新型生物标志物可提供早期干预并改善预后。目前正在研究几种治疗急性肾损伤的新药;然而,这种疾病的复杂性可能解释了仅针对众多相关系统之一的药物干预为何失败。血液净化可改善脓毒症相关性急性肾损伤预后的假说已引起广泛关注。关于基于聚甲基丙烯酸甲酯的连续性静脉-静脉血液滤过在脓毒症相关性急性肾损伤中的作用,已有新的相关研究结果报道。在此,我们对脓毒症相关性急性肾损伤病理生理学的进展及该领域潜在的治疗方法进行全面的文献综述。